We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1–6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen
Background: This phase I study was aimed at defining the toxicity profile and pathological response ...
This study was performed to assess the efficacy and safety of preoperative chemoradiation consisting...
Background: The conventional non-surgical treatment for locally advanced esophageal squamous cell Ca...
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with...
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with...
Background: To test the feasibility of incorporating a twice -weekly paclitaxel (Taxol) and cisplati...
BACKGROUND. A Phase II trial was conducted at the University of Michigan to determine the efficacy o...
Abstract Background Concurrent chemoradiotherapy is a standard modality for locally advanced esophag...
AbstractPurposeTo assess the benefits of aggressive chemoradiation therapy followed by surgery in re...
Background:Cisplatin-based chemoradiotherapy (CRT) has been a standard treatment for patients with l...
AbstractObjective: We sought to evaluate treatment response to a novel combined-modality treatment r...
[[abstract]]Background: We investigated the efficacy and safety of adding cetuximab into twice-weekl...
To investigate the time to progression (TTP) and overall survival in patients with previously untrea...
This study is performed to evaluate the response rate, time to progression and safety of the combina...
BACKGROUND: This multicenter phase II study investigated the efficacy and feasibility of preoperativ...
Background: This phase I study was aimed at defining the toxicity profile and pathological response ...
This study was performed to assess the efficacy and safety of preoperative chemoradiation consisting...
Background: The conventional non-surgical treatment for locally advanced esophageal squamous cell Ca...
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with...
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with...
Background: To test the feasibility of incorporating a twice -weekly paclitaxel (Taxol) and cisplati...
BACKGROUND. A Phase II trial was conducted at the University of Michigan to determine the efficacy o...
Abstract Background Concurrent chemoradiotherapy is a standard modality for locally advanced esophag...
AbstractPurposeTo assess the benefits of aggressive chemoradiation therapy followed by surgery in re...
Background:Cisplatin-based chemoradiotherapy (CRT) has been a standard treatment for patients with l...
AbstractObjective: We sought to evaluate treatment response to a novel combined-modality treatment r...
[[abstract]]Background: We investigated the efficacy and safety of adding cetuximab into twice-weekl...
To investigate the time to progression (TTP) and overall survival in patients with previously untrea...
This study is performed to evaluate the response rate, time to progression and safety of the combina...
BACKGROUND: This multicenter phase II study investigated the efficacy and feasibility of preoperativ...
Background: This phase I study was aimed at defining the toxicity profile and pathological response ...
This study was performed to assess the efficacy and safety of preoperative chemoradiation consisting...
Background: The conventional non-surgical treatment for locally advanced esophageal squamous cell Ca...